Post-cycle and ancillaries compared

Anastrozole vs tamoxifen

An aromatase inhibitor and an antiestrogen, with each figure tied to its own label or trial.

Anastrozole is a selective non-steroidal aromatase inhibitor that lowers serum estradiol, and tamoxifen is a nonsteroidal antiestrogen that competes with estradiol for the estrogen receptor.1,2 The Arimidex label gives a mean elimination half-life of 50 hours, and the tamoxifen label a terminal elimination half-life of about 5 to 7 days.1,2

The ATAC trial compared the two directly, randomising 9,366 postmenopausal women with operable breast cancer to anastrozole 1 mg daily, tamoxifen 20 mg daily or both for five years.1

FactAnastrozole (Arimidex)Tamoxifen (Nolvadex)
What it isA selective non-steroidal aromatase inhibitor1A nonsteroidal antiestrogen that competes with estradiol for the estrogen receptor2
How it comes1 mg tablets, in bottles of 301Tablets of 10 mg and 20 mg, for oral administration2
Half-life
  • Mean elimination half-life of 50 hours on the US label1
  • Near steady state at about 7 days of once daily dosing1
  • Terminal elimination half-life of about 5 to 7 days on the US label2
  • About 14 days for its metabolite N-desmethyl tamoxifen, at steady state in about 8 weeks2
Studied doses
  • US label: one 1 mg tablet once a day1
  • ATAC trial: 1 mg daily, tamoxifen 20 mg daily or both, in 9,366 postmenopausal women with operable breast cancer, for five years1
  • US label: 20 to 40 mg a day for breast cancer2
  • Prevention trial: 20 mg a day or placebo for 5 years, in 13,388 women at increased risk (6,681 on tamoxifen)4
StatusUS label: breast cancer in postmenopausal women (adjuvant early receptor-positive; first-line advanced receptor-positive or unknown; advanced after tamoxifen)1. WADA lists it among aromatase inhibitors (S4.1), prohibited at all times5US label: metastatic breast cancer in women and men, node-positive and node-negative breast cancer, DCIS after surgery and radiation, and lowering breast cancer incidence in women at high risk2. WADA lists it among anti-estrogenic substances (S4.2), prohibited at all times5

Get the app

Contents6
  1. 1The trial that compared them
  2. 2How they differ
  3. 3Logged in Milligram
  4. 4What is not known
  5. 5References
  6. 6Related pages

Last reviewed . Sources are listed below.

The trial that compared them

After a median follow-up of 68 months in 9,366 postmenopausal women, the ATAC report gives 575 disease-free survival events with anastrozole and 651 with tamoxifen, a hazard ratio of 0.87, and the label names disease-free survival as the trial's primary endpoint.3,1 The same report states that arthralgia and fractures were increased with anastrozole, and that anastrozole was associated with fewer gynaecological problems and vascular events than tamoxifen.3

At a median follow-up of 33 months, the arm given both showed no efficacy benefit over tamoxifen and was discontinued.1

How they differ

Tamoxifen reaches steady state in about 4 weeks and its metabolite N-desmethyl tamoxifen in about 8 weeks, while anastrozole approaches steady state at about 7 days.2,1 The tamoxifen label states that loss of libido and impotence have led men to stop tamoxifen, and that in oligospermic males given tamoxifen, LH, FSH, testosterone and estrogen levels were elevated.2

Logged in Milligram

  • Anastrozole (Arimidex): Too few people logged it to show a share.
  • Tamoxifen (Nolvadex): Too few people logged it to show a share.

Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.

What is not known

The tamoxifen label states that the effects of age, gender and race on its pharmacokinetics have not been determined.2 The Arimidex label states that efficacy has not been demonstrated for pubertal boys of adolescent age with gynecomastia.1

References

  1. ANI Pharmaceuticals, Inc. ARIMIDEX (anastrozole) tablet, prescribing information (ANI Pharmaceuticals, Inc.). Official label, 2026. DailyMed label
  2. Mayne Pharma. TAMOXIFEN CITRATE tablet, film coated. Drug label, 2022. DailyMed label
  3. Howell A, Cuzick J, Baum M, et al.; ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Randomised trial, 2005. PMID 15639680
  4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Randomised trial, 1998. PMID 9747868
  5. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. Regulator list, 2026. wada-ama.org